Triose phosphate isomerase, in converting dihydroxyacetone phosphate into glyceraldehyde 3-phosphate, catalyzes the transfer of a hydrogen atom from C-1 to C-2, that is, catalyzes an intramolecular oxidation-reduction. And in essence, after the enzyme reaction, the carbons C-1, C-2 and C-3 of the starting glucose to become equivalent, chemically indistinguishable, from the carbons C-6, C-5 and C-4, respectively.
Therefore, the net result of the the last two steps of glycolysis is the production of two molecules of glyceraldehyde 3-phosphate .
The ΔG°’ of the reaction is of kJ/mol ( kcal/mol), while the ΔG is kJ/mol ( kcal/mol). Although at equilibrium dihydroxyacetone phosphate represent about 96% of the trioso phosphates, the reaction proceeds readily towards the formation of glyceraldehyde 3-phosphate because of the subsequent step of the glycolytic pathway that removes the glyceraldehyde 3-phosphate produced.
One of the distinguishing features of triose phosphate isomerase is the great catalytic efficiency. The enzyme is in fact considered kinetically perfect . Why? The enzyme enhances the isomerization rate by a factor of 10 10 compared with that obtained with a catalyst such as acetate ion. Indeed, the K cat /K M ratio for the isomerization of glyceraldehyde 3-phosphate is equal to 2×10 8 M -1 s -1 , value close to the diffusion-controlled limit. Thus, the rate-limiting step in the reaction catalyzed by triose phosphate isomerase is diffusion-controlled encounter of enzyme and substrate.
From the energetic point of view, the last two steps of glycolysis are unfavorable, with ΔG°’ of kJ/mol ( kcal/mol), whereas the net ΔG°’ of the first five reactions is of kJ/mol ( kcal/mol), with a K eq of about . And it is the free energy derived from the hydrolysis two ATP that, under standard-state conditions, makes the value of the overall equilibrium constant close to one. If instead we consider ΔG, it is quite negative, - kJ/mol (- kcal/mol).
Adverse effects of testosterone supplementation may include increased cardiovascular events (including strokes and heart attacks ) and deaths based on three peer-reviewed studies involving men taking testosterone replacement.  In addition, an increase of 30% in deaths and heart attacks in older men has been reported.  Due to an increased incidence of adverse cardiovascular events compared to a placebo group , a Testosterone in Older Men with Mobility Limitations (TOM) trial (a National Institute of Aging randomized trial) was halted early by the Data Safety and Monitoring Committee .  On January 31, 2014, reports of strokes , heart attacks , and deaths in men taking FDA-approved testosterone-replacement led the FDA to announce that it would be investigating the issue.  Later, in September 2014, the FDA announced, as a result of the "potential for adverse cardiovascular outcomes", a review of the appropriateness and safety of Testosterone Replacement Therapy (TRT).    The FDA now requires warnings in the drug labeling of all approved testosterone products regarding deep vein thrombosis and pulmonary embolism . 
The Endocrine Society recommends against the therapeutic use of DHEA-S in both healthy women and those with adrenal insufficiency , as its role is not clear from studies performed so far.  The routine use of DHEA-S and other androgens is discouraged in the treatment of women with low androgen levels due to hypopituitarism , adrenal insufficiency , menopause due to ovarian surgery, glucocorticoid use, or other conditions associated with low androgen levels; this is because there are limited data supporting improvement in signs and symptoms with therapy and no long-term studies of risk.